Atea Pharmaceuticals Inc. (AVIR): Price and Financial Metrics

Atea Pharmaceuticals Inc. (AVIR): $4.50

0.42 (+10.29%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add AVIR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#252 of 380

in industry

AVIR Price/Volume Stats

Current price $4.50 52-week high $9.79
Prev. close $4.08 52-week low $2.94
Day low $4.10 Volume 1,290,900
Day high $4.52 Avg. volume 653,578
50-day MA $3.55 Dividend yield N/A
200-day MA $4.77 Market Cap 375.30M

AVIR Stock Price Chart Interactive Chart >


Atea Pharmaceuticals Inc. (AVIR) Company Bio


Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.


AVIR Latest News Stream


Event/Time News Detail
Loading, please wait...

AVIR Latest Social Stream


Loading social stream, please wait...

View Full AVIR Social Stream

Latest AVIR News From Around the Web

Below are the latest news stories about ATEA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AVIR as an investment opportunity.

Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences

Proposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its ShareholdersBOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that its Board of Directors unanimously rejected the unsolicited proposal from Tang Capital Partners, LP on behalf of Concentra Biosciences, LLC to acquir

Yahoo | May 30, 2023

Lordstown Motors and Atea Pharmaceuticals Stock See Action From Activist Investors

Lordstown Motors’ former CEO Steve burns lowered his stake in the maker of electric trucks. Atea Pharmaceuticals is evaluating an M&A offer.

Yahoo | May 26, 2023

Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences

BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding common shares of Atea for $5.75 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of Atea’s programs. Atea’s Board of Directors and management team regularly re

Yahoo | May 23, 2023

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Call Transcript May 8, 2023 Atea Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.43, expectations were $-0.48. Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals’ First Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only […]

Yahoo | May 10, 2023

Q1 2023 Atea Pharmaceuticals Inc Earnings Call

Q1 2023 Atea Pharmaceuticals Inc Earnings Call

Yahoo | May 9, 2023

Read More 'AVIR' Stories Here

AVIR Price Returns

1-mo 34.33%
3-mo 34.73%
6-mo -3.43%
1-year -42.31%
3-year N/A
5-year N/A
YTD -6.44%
2022 -46.20%
2021 -78.60%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!